CLINICAL_TRIALS trial_result · 2023-01-05

Clinical Trial Update: Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks [Phase 3]

Phase 3 trial assessing safety, efficacy, and pharmacokinetics of PRX-102 given IV every 4 weeks in Fabry disease completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Protalix | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-01-05